Top Markets
#1 GEKKO GEKKO +52.86%
#2 ADO Protocol ADO Protocol +38.50%
#3 Helium Helium +29.80%
#4 Pons Pons +28.26%
#5 TENDIES TENDIES +23.40%
#6 龙虾 (Lobster) 龙虾 (Lobster) +19.97%
#7 o1.exchange o1.exchange +18.32%
#8 Main Street Yield Main Street Yield +17.48%
#9 Nillion Nillion +16.96%
#10 Giggle Fund Giggle Fund +15.80%
Coin of the day
GEKKO GEKKO
Settings
Language
ENGLISH
Currency
USD
Theme
Nichi-Iko Pharmaceutical Co., Ltd. Nichi-Iko Pharmaceutical Co., Ltd.

Nichi-Iko Pharmaceutical Co., Ltd.

4541
Rank in Stocks #8954
Nichi-Iko Pharmaceutical Co., Ltd. actively manufactures, distributes, imports,... Nichi-Iko Pharmaceutical Co., Ltd. actively manufactures, distributes, imports, and sells a wide variety of pharmaceutical products. Operating through its Sagent Group and Nichi-Iko Group segments, the company primarily focuses on the development and production of generic drugs. Its extensive product line encompasses antidiabetic, antacid, and antireflux agents, as well as beta-blockers, hypnotics, sedatives, angiotensin II antagonists (including combinations with diuretics), dyslipidemic agents, and calcium antagonists. These offerings target conditions affecting the circulatory, digestive, respiratory, central, and peripheral nervous systems, among others. Beyond pharmaceuticals, the company is also involved in packaging design and exports its products internationally. Established in 1947 as Nihon Iyakuhin Kogyo Co., Ltd., the firm officially became Nichi-Iko Pharmaceutical Co., Ltd. in 2005 and is headquartered in Toyama, Japan.
Share Price
$0.22167204
Last synced: 2024-08-21
Market Cap
$1.13B
Change (1 day)
1.08%
Change (1 year)
0.00%
Country
JP
Trade Nichi-Iko Pharmaceutical Co., Ltd. (4541)

Category

Healthcare
Revenue for Nichi-Iko Pharmaceutical Co., Ltd. (4541)
Revenue in Aug 2026 TTM: 0
According to Nichi-Iko Pharmaceutical Co., Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Nichi-Iko Pharmaceutical Co., Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 $6.61B -
IN